T he incidence, morbidity, and mortality of intracerebral hemorrhage (ICH) have remained constant in highincome countries, with less hypertension-associated and more antithrombotic-associated ICH over time.
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Rankin Scale score at discharge ≤2. In addition, in-hospital, 3-month, and 12-month mortalities were predefined outcome measures.
Statistical Analyses
Statistical significance for intergroup differences was assessed by χ 2 test for categorical variables, and Mann-Whitney U and KruskalWallis tests for noncontinuous variables or skewed numeric variables. All tests were 2-tailed, and statistical significance was set at <0.05.
To test the independent prognostic value of the lipid levels on inhospital, 3-month, and 12-month mortalities, multivariable logistic regression models were constructed, adjusting for factors known to affect mortality after ICH (age, National Institutes of Health Stroke Scale, GCS, ICH volume, and ventricular location). 11 Because of collinearity, cholesterol and LDL levels were tested separately. Analyses were performed with SPSS version 19 (SPSS, Inc, Chicago, IL).
Results
The Statin users (n=187, 19%) were significantly older than nonusers, had more frequently comorbidities and prior cardiovascular medication, more often an modified Rankin Scale score >2, and had higher baseline GCS values (Table I in the online-only Data Supplement). There were no differences in baseline National Institutes of Health Stroke Scale, ICH volume, or intraventricular ICH location. Total cholesterol, LDL, and triglyceride levels were all significantly lower in statin users as compared with nonusers. There were no differences in modified Rankin Scale score at discharge, inhospital, 3-month, or 12-month mortalities in statin users, as compared with nonusers (Table II in the online-only Data Supplement).
In univariate analysis, lower cholesterol and LDL levels were associated with in-hospital, 3-month, and 12-month mortalities, and poor modified Rankin Scale score at discharge rates (Table III in the online-only Data Supplement). In multivariable analysis higher LDL levels were independently associated with in-hospital (odds ratio, 0.54 [95% confidence interval, 0.31-0.93]; P=0.028) but not with 3-month or 12-month mortality, whereas cholesterol was not associated with mortality (Table IV in the online-only Data Supplement).
Discussion
Our study did not find any association between premorbid statin use and outcome of ICH, which is in line with some recent studies. [12] [13] [14] The statin users were older, had more frequent comorbidities and prior disabilities compared with nonusers in our study, unlike in earlier studies where the statin users have both achieved better outcomes and have been less disabled. 5, 6 Statin therapy has been recommended to be avoided in some patients with a high risk of ICH, as in amyloid angiopathy where quality-adjusted life-year gain has been reported in patients avoiding statins. 15 However, as prior use of statins did not increase ICH mortality in our study, continuing statin therapy may outweigh the disadvantages of their use in most ICH patients with multiple vascular risk factors by preventing ischemic strokes. 12 Lipids have been suggested to act as biological markers of ICH severity, and our finding that baseline GCS was slightly higher in patients with lower lipid levels is in line with earlier observations. 7 Low cholesterol levels have been thought to decrease vessel resistance to rupture, as cholesterol is essential for normal membrane fluidity. 8 An inverse association of lipid levels with both short-term and long-term mortality has been reported earlier. 7, 8, 10 Although the overall mortality was increased in patients with lower total cholesterol and LDL levels in our univariate analyses, we found an independent association only of lower LDL levels with in-hospital mortality. One of the reasons for this could be the fact that patients with known lipid levels had much lower mortality rates compared with the overall rate in the current and other prospective studies. 5, 7 We cannot exclude the possibility that most of the patients with missing lipid data had severe ICH and died before the blood samples could have been drawn; this is a limitation in our study. The strengths of our study are the large population and mortality data available for several time points, which allows better comparisons with previous reports. ICH, Intracerebral Hemorrhage; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; GCS, Glasgow Coma Scale. Any heart disease includes coronary artery bypass surgery, percutaneous transluminal coronary angioplasty, morbus cordis coronarius, acute myocardial infarct, heart failure, and atrial fibrillation. COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack; LDL, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol. Intergroup differences were assessed by Chi-square or Mann-Whitney U test.
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